Skip to main content

World Fusion, Lumenogix to Integrate Technologies to Enable NGS-based Drug Discovery

NEW YORK (GenomeWeb) – World Fusion and Lumenogix today announced a strategic partnership to integrate their technologies.

World Fusion will integrate its Life Sciences Knowledge Bank for accelerating drug discovery with Lumenogix's Bioinformatics-in-a-Box for next-generation sequencing data analysis. The new system will link NGS-processed results managed by Lumenogix's technology with small molecule and protein data managed by LSKB, enabling pharma to take advantage of the opportunities offered by NGS technology, the partners said.

Financial and other terms of the deal were not disclosed.

"World Fusion offers us an opportunity to deliver chemical, gene, protein, and disease information to our clients," Lumenogix CEO Boris Umylny said in a statement. "Together with World Fusion we will deliver a complete solution to the pharmaceutical industry and help them solve the data mining challenges inherent in high-throughput sequencing data."

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.